SGO 2024 Insights: "Platinum-Free Interval & Response to Platinum Retreatment or Lenvatinib/Pembro in Patients With Recurrent Endometrial Cancer"

0 views
April 12, 2024
Comments 1
Login to view comments. Click here to Login